Keros Therapeutics, Inc. (KROS) stock
KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$11.08−0.31 (-2.72%)
Close on Nov 20, 2026Market cap $219.69MP/E –Yield –
Keros Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Keros Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$48.49M, down 191.3% year over year. For fiscal 2025 it was $105.95M. The highest annual figure on record is $105.95M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $105.95M | – |
| FY2024 | Dec 31, 2024 | -$162.80M | – |
| FY2023 | Dec 31, 2023 | -$126.97M | – |
| FY2022 | Dec 31, 2022 | -$71.30M | – |
| FY2021 | Dec 31, 2021 | -$63.17M | – |
| FY2020 | Dec 31, 2020 | -$37.19M | – |
| FY2019 | Dec 31, 2019 | -$16.27M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$20.58M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.60M | -102.2% |
| Q4 FY2025 | Dec 31, 2025 | -$27.43M | – |
| Q3 FY2025 | Sep 30, 2025 | $3.12M | – |
| Q2 FY2025 | Jun 30, 2025 | -$30.34M | – |
| Q1 FY2025 | Mar 31, 2025 | $160.61M | – |
| Q4 FY2024 | Dec 31, 2024 | -$46.30M | – |
| Q3 FY2024 | Sep 30, 2024 | -$30.89M | – |
| Q2 FY2024 | Jun 30, 2024 | -$40.11M | – |
| Q1 FY2024 | Mar 31, 2024 | -$45.51M | – |
| Q4 FY2023 | Dec 31, 2023 | -$26.00M | – |
| Q3 FY2023 | Sep 30, 2023 | -$34.53M | – |
| Q2 FY2023 | Jun 30, 2023 | -$31.14M | – |
| Q1 FY2023 | Mar 31, 2023 | -$35.30M | – |
| Q4 FY2022 | Dec 31, 2022 | -$21.79M | – |
| Q3 FY2022 | Sep 30, 2022 | -$24.78M | – |
| Q2 FY2022 | Jun 30, 2022 | -$23.16M | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.57M | – |
| Q4 FY2021 | Dec 31, 2021 | -$19.72M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.59M | – |
| Q2 FY2021 | Jun 30, 2021 | -$18.15M | – |
| Q1 FY2021 | Mar 31, 2021 | -$10.72M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.05M | – |
| Q3 FY2020 | Sep 30, 2020 | -$10.89M | – |
| Q2 FY2020 | Jun 30, 2020 | -$9.96M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.30M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.52M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.04M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.20M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.51M | – |
See a number that looks wrong?